RATIONALE: Individuals with trichotillomania often report significant difficulty resisting the urges and drive to pull hair. OBJECTIVES: The aim of this study is to examine whether modafinil improves motor inhibitory control, and other cognitive functions, in trichotillomania. METHODS:Eighteen subjects with trichotillomania (mean age 33.4 ± 12.8 years; 78% female) received a single dose of modafinil (200 mg) and placebo in a crossover double-blind design. Neurocognitive performance was assessed using the stop-signal, pattern recognition, rapid visual information processing and Tower of London tasks. RESULTS: No effects of modafinil on cognition approached statistical significance on the test measures examined (all p > 0.10). CONCLUSIONS: These results suggest that modafinil may not be useful for targeting impulse dyscontrol in trichotillomania. However, it remains possible that relatively small effects of modafinil on cognition could exert larger downstream effects on overt behaviour. Further trials using modafinil and other pro-cognitive agents are warranted.
RCT Entities:
RATIONALE: Individuals with trichotillomania often report significant difficulty resisting the urges and drive to pull hair. OBJECTIVES: The aim of this study is to examine whether modafinil improves motor inhibitory control, and other cognitive functions, in trichotillomania. METHODS: Eighteen subjects with trichotillomania (mean age 33.4 ± 12.8 years; 78% female) received a single dose of modafinil (200 mg) and placebo in a crossover double-blind design. Neurocognitive performance was assessed using the stop-signal, pattern recognition, rapid visual information processing and Tower of London tasks. RESULTS: No effects of modafinil on cognition approached statistical significance on the test measures examined (all p > 0.10). CONCLUSIONS: These results suggest that modafinil may not be useful for targeting impulse dyscontrol in trichotillomania. However, it remains possible that relatively small effects of modafinil on cognition could exert larger downstream effects on overt behaviour. Further trials using modafinil and other pro-cognitive agents are warranted.
Authors: Danielle C Turner; Trevor W Robbins; Luke Clark; Adam R Aron; Jonathan Dowson; Barbara J Sahakian Journal: Psychopharmacology (Berl) Date: 2002-11-01 Impact factor: 4.530
Authors: Nora D Volkow; Joanna S Fowler; Jean Logan; David Alexoff; Wei Zhu; Frank Telang; Gene-Jack Wang; Millard Jayne; Jacob M Hooker; Christopher Wong; Barbara Hubbard; Pauline Carter; Donald Warner; Payton King; Colleen Shea; Youwen Xu; Lisa Muench; Karen Apelskog-Torres Journal: JAMA Date: 2009-03-18 Impact factor: 56.272
Authors: Christopher A Flessner; Douglas W Woods; Martin E Franklin; Nancy J Keuthen; John Piacentini Journal: Child Psychiatry Hum Dev Date: 2008-09-09
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Samuel R Chamberlain; Brian L Odlaug; Vasileios Boulougouris; Naomi A Fineberg; Jon E Grant Journal: Neurosci Biobehav Rev Date: 2009-02-20 Impact factor: 8.989
Authors: Samuel R Chamberlain; Naomi A Fineberg; Andrew D Blackwell; Trevor W Robbins; Barbara J Sahakian Journal: Am J Psychiatry Date: 2006-07 Impact factor: 19.242
Authors: Jacob Hoffman; Taryn Williams; Rachel Rothbart; Jonathan C Ipser; Naomi Fineberg; Samuel R Chamberlain; Dan J Stein Journal: Cochrane Database Syst Rev Date: 2021-09-28